Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
El factor de transcripción nuclear kappa en las enfermedades humanas
Resumen
El factor de transcripción nuclear kappa B (NF-κB) fue descrito por primera vez en 1986. Actualmente ha sido ligado a un sinnúmero de enfermedades metabólicas, inflamatorias y diversos tipos de cáncer, y seguirá siendo de interés en diversos procesos de enfermedad inflamatorios, infecciosos y neoplásicos. El descubrimiento de este factor ha logrado ampliar nuestro conocimiento sobre la regulación de la inflamación y las enfermedades crónicas, así como de los fármacos para tratar dichas enfermedades.
Palabras clave
Texto completo:
PDFReferencias
Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46(5):705-716.
Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A. The transcription factor nuclear factor kappa B and cancer. Clin Oncol (R Coll Radiol) 2007;19(2):154-161.
Ghosh, S, May M, Kopp E. NF-kappa B and Rel proteins: evolutionarily conserved mediators of the immune response. Annu Rev Immunol 1998;16: 225-260.
Yamamoto Y, Gaynor RB. Therapeutic potential of inihibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107(2):135-142.
Bian X, McAllister-Lucas LM, Shao F, Schumacher KR, Feng Z, Porter AG, Castle VP, Opipari AW Jr. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem 2001;276(52):48921-48929.
Brandt S, Kwok T, Harting R, Konlg W, Backert S. NF-kappa B activation and potentiation of proinflammatory responses by the Helicobacter Pylori CagA protein. Proc Natl Acad Sci USA 2005;102 (26):9300-9305.
Abdel-Latif MM, O’Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, Reynolds JV. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett’s metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004;239(4):491-500.
Jimi E, Gosh S. Role of nuclear factor-kappaB in the immune system and bone. Immunol Rev 2005; 208:80-87.
Chen CC, Rosenbloom CL, Anderson DC, Maning AM. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expresion by inhibitors of I kappa-B alpha phosphorilation. J Immunol 1995;155(7):3538-3545.
Tak PP, Firestein GS. NF-kappa B: A key role in inflammatory diseases. J Clin Invest 2001;107 (1):7-11.
Han ZN, Boyle DL, Manning AM, Firestein GS. AP-I and NF-kappa B regulation in rheumatoid arthritis and murine collagen-induced arthritis. Auto-immunity 1998;28(4):197-208.
Sakurai PP, Sakurai H, Hisada Y, Ueno M, Sugiura M, Kawashima K, Sugita T. Activation of transcription factor NF-kappa B in experimental glomerulonephritis in rats. Biochem Biophys Acta 1996; 1316(2):132-138.
Yang F, de Villiers WJ, Lee EY, McClain CJ, Varilek GW. Increased nuclear factor-kappa B activation in colitis of inteurleukin-2-deficient mice. J Lab Clin Med 1999;134(4):378-385
Hart LA, Krishnan VL, Adcock IM, Barnes PJ, Chung KF. Activation and localization of transcription factor, nuclear factor-kappa B in asthma. Am J Resp Crit Care Med 1998;158(5 Pt 1):1585-1592
Creus KK, De Paepe B, Werbrouck BF, Vervaet V, Weis J, De Bleecker JL. Distribution of the NF-kappaB complex in the inflammatory exudates characterizing the idiopathic inflammatory myopathies. Ann N Y Acad Sci 2009;1173:370-377.
DeLuca C, Petropolous L, Zmeureanu D, Hiscott J. Nuclear I kappa beta maintains persistent NF-kappa B activation in HIV-1 infected myeloid cells. J Biol Chem 1999;274(19):13010-13016.
Hiscott J, Kwon H, Genin P. Hostile takeovers: viral appropriation of the NF- kappa B pathway. J Clin Invest 2001;107(2):143-151.
Paine E, Scheinman R, Baldwin A, Raab-Traub N. Expression of LMP1 in epithelial cells leads to activation of a select subset of NF-kappa B/Rel family proteins. J Virol 1995;69(7):4572-4576.
Tai DI, Tsai SL, Chang YH, Huang SN, Chen TC, Chang KS, Liaw YF. Constitutive activation of nuclear factor kappa B in hepatocellular carcinoma. Cancer 2000;89(11):2274-2281.
Li N, Karin M. Is NF-kappa B the sensor of oxidative stress? FASEB J 1999;13(10):1137-1143.
Brand K, Eisele T, Kreusel U, Page M, Page S, Haas M, Gerling A, et al. Dysregulation of monocytic nuclear factor-kappa B by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 1997; 17(10):1901-1909.
Mazière C, Mazière JC. Activation of transcription factors and gene expression by oxidized low-density lipoprotein. Free Radic Biol Med 2009; 46(2):127-137.
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor alpha: a direct role in obesity-linked insulin resistance. Science 1993;259(5091):87-91.
Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115(5):1111-1119.
Escárcega RO, García-Carrasco M, Fuentes-Alexandro S, Jara LJ, Rojas-Rodríguez J, Escobar-Linares LE, et al. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmun Rev 2006;6(1):48-53.
Ghosh S, May M, Kopp E. NF-kappa B and Rel proteins: evolutionarily conserved mediators of the immune response. Annu Rev Immunol 1998;16: 225-260.
Luo JL, Kamata H, Karin M. IKK/NF-kappa B signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005;115(10): 2625-2632.
Monks NR, Biswas DK, Pardee AB. Blocking anti-apoptosis as a strategy for cancer chemotherapy. NF-kappa B as a target. J Cell Biochem 2004;92 (4):646-650.
Orlowski RZ, Baldwin AS Jr. NF-kappa B as a therapeutic target in cancer. Trends Mol Med 2002;8(8): 385-389.
Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107(2):135-142.
Wahl C, Liptay S, Adler G, Schmid RM. Sulfa-salazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1997;101(5):1163-1174.
Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270(5234): 286-290.
Enlaces refback
- No hay ningún enlace refback.